SCHEMBL2828351

SCHEMBL2828351

NNC(=O)C1CCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19550602 1.00
SCHEMBL19550635 1.00
SCHEMBL19551083 0.88 HDAC3 (0.45)
SCHEMBL19550760 0.88 HDAC3 (0.45)
SCHEMBL19550901 0.88 HDAC3 (0.45)
SCHEMBL364361 0.86 HDAC1 (0.41)
SCHEMBL19550888 0.81
SCHEMBL28379975 0.81
SCHEMBL6240462 0.80
SCHEMBL2049787 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551490-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2026-02-17 US disclosed
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-10-09 US disclosed
EP-4610260-A1 ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Shanghai Shenshi Wise Technology Co., Ltd. (CN) 2025-09-03 EP disclosed
CN-112384515-B Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors 因赛特公司 2024-12-10 CN disclosed
US-20240400552-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2024-12-05 US disclosed
CN-117946111-A Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2024-04-30 CN disclosed
CN-117903140-A Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors 因赛特公司 2024-04-19 CN disclosed
US-20230405016-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2023-12-21 US disclosed
US-20230357255-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2023-11-09 US disclosed
CN-116763791-A Compounds and methods of use thereof 普拉克西斯精密药物股份有限公司 2023-09-19 CN disclosed
US-20120264737-A1 Heterocyclic Modulators of Lipid Synthesis 3-V BIOSCIENCES, INC. (US) 2012-10-18 US disclosed
US-20120264737-A1 Heterocyclic Modulators of Lipid Synthesis 3-V BIOSCIENCES, INC. (US) 2012-10-18 US disclosed
WO-2012122391-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. (US) 2012-09-13 WO disclosed
WO-2012122391-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. (US) 2012-09-13 WO disclosed
WO-2012068234-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-05-24 WO disclosed
EP-1937688-B1 IMIDAZO BENZODIAZEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
US-7507729-B2 for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine HOFFMANN-LA ROCHE INC. (US) 2009-03-24 US disclosed
EP-1937688-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
WO-2007042421-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-19 WO disclosed
US-20070082890-A1 Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT 2007-04-12 US disclosed